Overactive bladder medication adherence when medication is free to patients
- PMID: 20092838
- DOI: 10.1016/j.juro.2009.11.026
Overactive bladder medication adherence when medication is free to patients
Abstract
Purpose: We examined overactive bladder medication compliance in a health care system in which patients do not pay for medication.
Materials and methods: Pharmacy dispensing records were reviewed for antimuscarinic agents from January 2003 to December 2006 for the United States Military Health System National Capital Region. Medication nonpersistence, switching and adherence were examined. Kaplan-Meier survival analysis was done to compare medication persistence duration.
Results: Overactive bladder medications were dispensed to 7,879 adults. Tolterodine extended release (4,716 patients or 60%) and oxybutynin immediate release (2,003 or 25.5%) were most commonly prescribed. The medication nonpersistence rate, defined as the proportion of patients who never refilled a prescription for antimuscarinics during the study period, was 35.1% (2,760 of 7,858). Of 5,098 patients who refilled a prescription 1,305 changed the medication or dose at least once for a medication switch rate of 25.6%. The overall median medication possession ratio, defined as the total days of medication dispensed except for the last refill divided by the number of days between the first dispense date and the last refill date, was 0.82 in all cases. Men had a significantly higher median medication possession ratio than women (0.86 vs 0.81, p <0.001). Of patients who obtained at least 1 refill women remained on medication longer than men (median 606 vs 547 days, p = 0.01). Patients on tolterodine extended release had a higher medication nonpersistence rate than those on oxybutynin immediate release (0.89 vs 0.68, p <0.01). There was no difference between extended release medications.
Conclusions: In a health care system in which patients do not pay for medications 35% of patients did not refill a prescription for overactive bladder medication, similar to previous reports. However, other measures of medication compliance were higher than those published previously in systems with copays.
2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Re: Overactive bladder medication adherence when medication is free to patients: C. L. Sears, C. Lewis, K. Noel, T. S. Albright and J. R. Fischer J Urol 2010; 183: 1077-1081.J Urol. 2010 Oct;184(4):1575. doi: 10.1016/j.juro.2010.06.030. Epub 2010 Aug 21. J Urol. 2010. PMID: 20728905 No abstract available.
Similar articles
-
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.J Manag Care Pharm. 2008 Apr;14(3):291-301. doi: 10.18553/jmcp.2008.14.3.291. J Manag Care Pharm. 2008. PMID: 18439051 Free PMC article.
-
Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.BJU Int. 2010 Jul;106(2):268-74. doi: 10.1111/j.1464-410X.2009.09073.x. Epub 2009 Nov 17. BJU Int. 2010. PMID: 19922546
-
Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.Am J Manag Care. 2005 Jul;11(4 Suppl):S140-9. Am J Manag Care. 2005. PMID: 16161387
-
Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.Curr Med Res Opin. 2007 Aug;23(8):1903-12. doi: 10.1185/030079907X210598. Curr Med Res Opin. 2007. PMID: 17610806 Review.
-
Tolterodine for treatment of overactive bladder.Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.
Cited by
-
β3-receptor agonists for overactive bladder--new frontier or more of the same?Curr Urol Rep. 2013 Oct;14(5):435-41. doi: 10.1007/s11934-013-0335-8. Curr Urol Rep. 2013. PMID: 23677692 Review.
-
Qualitative exploration of the modifiable factors for medication adherence among subsidised and self-paying patients in Malaysia.BMC Health Serv Res. 2018 Aug 6;18(1):605. doi: 10.1186/s12913-018-3417-y. BMC Health Serv Res. 2018. PMID: 30081892 Free PMC article.
-
Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer.Am Health Drug Benefits. 2016 Sep;9(6):343-353. Am Health Drug Benefits. 2016. PMID: 27924187 Free PMC article.
-
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.BMJ Open. 2018 Nov 21;8(11):e021889. doi: 10.1136/bmjopen-2018-021889. BMJ Open. 2018. PMID: 30467131 Free PMC article.
-
A comparison of medication adherence between subsidized and self-paying patients in Malaysia.Malays Fam Physician. 2018 Aug 31;13(2):2-9. eCollection 2018. Malays Fam Physician. 2018. PMID: 30302177 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical